Takeda Pharmaceutical Company has entered a global strategic partnership with China’s Innovent Biologics to acquire rights to two late-stage investigational oncology medicines and an option on an early-stage program, the companies announced October 22. Under the agreement, Takeda will pay
“CDMOs are partners with deep, extensive technical expertise that can be leveraged strategically—not just a restaurant where you pick from a menu.” Marta Kijanka, founder of MK Bioconsultancy, is a strategic project manager and CMC consultant who guides early-stage biotech
Successful biotech-CDMO partnerships require distinct capabilities at different clinical stages—and recognizing when to evolve your outsourcing strategy can make or break a development program. The priorities that matter in Phase 1, including development expertise and hands-on collaboration, give way to
At Nordic Life Science Days (NLSDays), a panel of leading Nordic investors and biopharma leaders explored how Europe’s life science financing landscape is evolving. Moderated by Renee Lucander, CEO of Hansa Biopharma, the discussion brought together Sonia Benhamida (Managing Director,
“The complexity is there’s an antibody component, linker-payloads with highly potent toxic agents that need high containment, and linking a biologic with a highly potent small molecule – it’s inherently challenging.” Dr. Harch Ooi, VP of Manufacturing and Chemistry at
President Donald Trump’s administration has exempted generic drugs from its pharmaceutical tariff policy, according to reports emerging this week. The decision provides significant relief to India’s pharmaceutical industry, which supplies approximately 35% of ingredients used in generic drugs consumed in
Tony Watson, Director of Procurement at Accord Healthcare, believes relationships are everything: “We spend our entire careers working on this network, but it can deliver so much more. If I could do one thing with CDMOs and our business support
How can integrated supply planning between sponsors and contract development and manufacturing organizations (CDMOs) improve resilience and cost control? This question has taken on new urgency as drug shortages in the U.S. continue to persist and geopolitical tensions reshape global
The UK government has developed proposals to increase NHS spending on pharmaceuticals by 15-25%, according to multiple reports, as officials attempt to resolve an escalating standoff with the pharmaceutical industry while simultaneously preparing for potential US tariffs under President Trump’s
Cytiva’s third Global Biopharma Index reports a decline in overall industry resilience amid ongoing talent shortages and increasing regulatory pressures. Every two years, Cytiva surveys 1,250 biopharma executives across 22 countries, asking them to rate the industry ecosystem on a
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
